Tim Kruser (@TimothyKruserMD) header
Tim Kruser (@TimothyKruserMD) profile picture

#Radonc, brain tumor & lung cancer specialist @TurvilleBay Outspoken advocate for my patients & field. Dad. #btsm #lcsm

Madison, WI
Joined October 2017
Photo by Tim Kruser (@TimothyKruserMD)Photo by Tim Kruser (@TimothyKruserMD)Photo by Tim Kruser (@TimothyKruserMD)Photo by Tim Kruser (@TimothyKruserMD)Photo by Tim Kruser (@TimothyKruserMD)Photo by Tim Kruser (@TimothyKruserMD)Photo by Tim Kruser (@TimothyKruserMD)Photo by Tim Kruser (@TimothyKruserMD)Photo by Tim Kruser (@TimothyKruserMD)Photo by Tim Kruser (@TimothyKruserMD)
I think we need to all just need pause & reflect. A football field worth of oncologists are here to hear a REAL DEBATE on a question we wouldn’t have asked 10 years ago. CURING metastatic disease with RT + IO?? What an exciting time to be an oncologist! #astro19
10
60
7
277
Lastly, we were also able to utilize the RTOG-0539 clinical trial cases for biomarker discovery and build multiple molecular predictive models of response to RT that were able to predict PFS following RT in meningiomas better than WHO grade alone including being able to identify RT-resistant meningiomas in each WHO grade
1
2
9
1,785
Glad to share some of my PhD work on using molecular classification to predict outcomes following surgery and radiotherapy in meningiomas published in @NatureMedicine. Grateful to @gelarehzadeh and @FarshadNassiri for helping guide this work and to our collaborators, reviewers, and funding agencies. nature.com/articles/s41591-0…
12
15
4
109
14,311
The Lahey Lung Cancer Screening program has surpassed 30,000 scans 10,500 patients scanned 382 lung cancers detected Cancer detection rate of 3.65% 0.0095 rate of any invasive procedure in patients without cancer Lung Cancer Screening is SAFE and EFFECTIVE
6
17
91
5,575
What I learned in 🇨🇱 today … $5mill = one #radiotherapy machine☢️, can treat 10k patients. $5mill = 135 patients worth of trastuzumab. 🧐 @TheLancetOncol - tinyurl.com/6bry9a2a “an essential pillar in multi-D oncology…an inexpensive modality” - 👏🏽 well said @TargetingCancer
9
86
11
220
34,807
3/ There are >dozen clinical trials of SABR for primary RCC – outlined in @ISRSy practice guideline - shorturl.at/suPTW – compared to zero for thermal ablation. The weight of evidence is with SABR, not TA, and is arguably the preferred modality for non-surgical therapy
1
4
1
26
2,668
So let me get this straight. More people in the U.S. die of lung cancer than die of breast, colorectal, and prostate cancer combined, and lung cancer screening rates are lower, yet @TODAYshow fails to mention it in their cancer screening segment? Who is their medical consultant?
We appreciate @TODAYshow for raising awareness of cancer screenings. However, we would have loved to have seen #lungcancer included. Lung cancer is the deadliest cancer. But only 4.5% of high risk Americans are getting screened. We need a segment on lung cancer screening! #LCAM🤍
6
29
1
78
17,215
I'm increasingly escalating RT dose for high-risk #meningioma in my practice @UCSF @UCSFCancer @NeurosurgUCSF. There is retrospective data in support of this approach, and now we have prospective data from @maxiydeng1994 in @NeuroOnc! Summary here: academic.oup.com/neuro-oncol…
1
9
1
38
5,806
Randomised CURB trial published in The Lancet: 👉 PFS increase by factor of FOUR (!) in oligoprogressive metastatic NSCLC pts by SBRT plus SoC vs SoC systemic Tx only 👉 SBRT with minimal added toxicity 16% G2+ Precision local SBRT🤝precision systemic TX thelancet.com/journals/lance…
2
63
3
127
33,600
📢Do you remember this excellent letter? it seems like so little time has passed..similar trial omitting RT in BM 🟰same answer!! "caution against overinterpretation of Atezo-Brain study and its impact on the management of intracranial disease in NSCLC patients"
1
1
5
773
Even in the ePET neg group with Hodgkin's Lymphoma, we cannot omit RT. H10 long-term FU showed. ePET + No difference between standard ABVD & exp intensified BEACOPPesc. Also icing on the cake no increase in second malignancies.
3
43
3
75
11,770
In three recent publications @jackykruser (@uw_APCC)—who just won the department's 2023 Junior Faculty Outstanding Research Award—shows how closer attention to communication can lead to meaningful changes in critical care practice: medicine.wisc.edu/news/jacqu…
4
20
1,827
Tim Kruser retweeted
What are the cognitive outcomes for glioma w/ modern focal RT? · Prospective Study F/U up to 11 years! · Stable w/some improvement · Despite more aggressive tumors outcomes comparable to Watchful-Waiting cohort rdcu.be/dmmHV
3
19
1
51
6,119
🧵5/ Tumour size ⬆️⬆️ than RCTs of PN v RN. Toxicity acceptable. As yet, there are no published clinical trials of thermal ablation; therefore, SABR is now a acceptable standard of care for inoperable RCC. FASTRACK II findings should lead to an RCT vs surgery. #ASTRO23 #radonc
7
41
2
115
15,669
Dr Denise Bernhardt shows RCT of #radiosurgery versus whole brain #radiotherapy for small cell #lungcancer. ➡️Primary endpoint cognitive decline. #lcsm ➡️ 24% decline in WBRT versus 7% in SRS alone OS data to mature!👏🏽👏🏽👏🏽 #ASTRO23
2
46
4
120
14,549
The Italian trial was fantastic. Really demonstrated what many radiation oncologists that specialize in mesothelioma had been seeing in their clinic. Hemithoracic radiation is much less morbid than surgery which likely explains the different outcome in the two trials.
Will def be an uphill battle for local tx after MARS2. I keep coming back to the trial by Trovo et al. (redjournal.org/article/S0360…), which has not received the attention it deserves IMO. Perhaps chemo/IO + RT (IMRT; moderate dose) could find balance between local control & tox?
1
13
36
5,425
Will def be an uphill battle for local tx after MARS2. I keep coming back to the trial by Trovo et al. (redjournal.org/article/S0360…), which has not received the attention it deserves IMO. Perhaps chemo/IO + RT (IMRT; moderate dose) could find balance between local control & tox?
1
8
4
25
10,724
The EORTC is conducting a consensus project to establish a consensual definition of resectability in stage III NSCLC. Bulky N2, invasive N2, N3-combinations were considered unresectable and should NOT be operated even after neoadjuvant chemo/RT outside clinical studies.#WCLC
3
79
5
188
23,527